Executive Summary

High-frequency ultrasound provides precise, non-invasive, and longitudinal quantification of tumor volume and vascularity in rodent xenograft models. This imaging modality overcomes the inherent limitations and variability of traditional caliper measurements, generating higher-fidelity data to support efficacy assessments for complex oncology therapeutics. By enabling each animal to serve as its own control, this technique improves statistical power, reduces animal usage in alignment with the 3Rs, and provides earlier, more robust insights into mechanism of action, de-risking the path to IND submission.

Quantitative Advantages in Xenograft Efficacy Studies

Traditional caliper measurements, while standard, introduce significant variability and are limited to two-dimensional approximations of tumor size. This method is often inaccurate for tumors with irregular growth patterns and provides no insight into the underlying tumor microenvironment.

High-frequency ultrasound offers a superior alternative by providing:

• 3D Volumetric Analysis: Captures the complete tumor volume for a more accurate assessment of tumor growth or regression.

• Intra-Tumoral Detail: Visualizes internal structures, including necrotic regions, which is valuable for assessing therapeutic response.

• Vascularity Assessment: Utilizes Power Doppler imaging to quantify blood flow, offering a direct measure of angiogenesis or anti-angiogenic drug effects.

This level of detail provides the robust in vivo data needed to make confident development decisions.

Strategic Applications for Advanced Therapies

The value of precise, longitudinal imaging is amplified when evaluating novel therapeutic platforms where mechanism of action is closely tied to physiological changes within the tumor.

For instance, understanding the principles of vector-mediated protein expression is informative. Studies leveraging AAV vectors to induce neovascularization (PMID: 15793254) underscore the need for sensitive tools that can track vascular changes over time. Similarly, ultrasound can provide direct, in-life evidence of efficacy for anti-angiogenic agents by quantifying reductions in tumor blood flow.

When assessing targeted delivery systems, such as AAV-based vectors designed to inhibit tumor growth (PMID: 30154145), early and accurate detection of tumor stasis is a primary objective. Longitudinal ultrasound provides this data weeks before terminal endpoints, confirming target engagement and informing dose-response relationships. This early data is a key component of building the robust preclinical package required to meet an 18-24 month IND timeline.